Recent Advances in Adjuvant Pharmacotherapy for Neonatal Indirect Hyperbilirubinemia: A Narrative Review

Context: Hyperbilirubinemia is a common cause for diagnostic work-up and therapeutic intervention in neonates needs convenient, quick, safe treatment modality. Phototherapy the most neonatal jaundice; however, complementary still needed. Despite identification of enzymatic pathways bilirubin catabolism, few pharmacological interventions have been found to be effective reducing bilirubin, along with traditional phototherapy. This review was conducted evaluate recent pharmacotherapies as adjuvants phototherapy indirect hyperbilirubinemia (IHB). Evidence Acquisition: study carried out through literature search keywords Infant, Newborn, Indirect Hyperbilirubinemia, combined Drug Therapy, PubMed, Scopus, International Statistical Institute, Web Science, Cochrane, Embase databases. included relevant articles (i.e., randomized controlled trials, observational studies, guidelines, reviews) written English published between 2012 - 2022. Results: narrative first assessed define IHB its etiology. Then, efficacy side effects pharmacologic agents were discussed. Additionally, this reviewed safety drugs prescribed prevent jaundice. Conclusions: The best drug adjuvant pharmacotherapy, addition phototherapy, jaundice has not identified. use probiotics, prebiotics, synbiotics, ursodeoxycholic acid (UDCA) recently increasing, beneficial results observed studies. agar, charcoal, fibrate, phenobarbital had minor role years. There conflicting about herbal intravenous immunoglobulin (IVIG), metalloporphyrin, albumin also limited severe or immune-related cases. prescription aforementioned sometimes different results. Therefore, further research regard necessary.